Fri, March 30, 2012
Thu, March 29, 2012
Wed, March 28, 2012
Tue, March 27, 2012
Mon, March 26, 2012
Sun, March 25, 2012
Sat, March 24, 2012
Fri, March 23, 2012
Thu, March 22, 2012
Wed, March 21, 2012
Tue, March 20, 2012
Mon, March 19, 2012

ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting


//health-fitness.news-articles.net/content/2012/ .. ociation-for-cancer-research-annual-meeting.html
Published in Health and Fitness on Monday, March 26th 2012 at 4:50 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2012, taking place Saturday, March 31 through Wednesday, April 4, 2012, in Chicago.

Listed below are the details of presentations at AACR that describe ARIADas product candidates or research programs. There will be three presentations of data on ARIADas investigational targeted therapies, ponatinib and AP26113; and one presentation of work on choline kinase, a discovery program which is not being pursued further at this time. Each presentation is currently available in abstract form:

Title: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFR'/' and FGFR1
Date & Time: Sunday, April 1, 1:00a"5:00 p.m. (Poster)
Abstract: #853
Location: Hall F, Poster Section 32
Title: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC
Date & Time: Monday, April 2, 8:00 a.m.a"12:00 p.m. (Poster)
Abstract: #1794
Location: Hall F, Poster Section 29
Title: Fibroblast growth factors in head and neck cancer: Genetic alterations and therapeutic targeting with ponatinib
Date & Time: Monday, April 2, 1:00a"5:00 p.m. (Poster)
Abstract: #2832
Location: Hall F, Poster Section 32
Title: Small molecule inhibitors of choline kinase lead to reduced phosphocholine levels and induction of apoptosis in cancer cells
Date & Time: Tuesday, April 3, 8:00 a.m.a"12:00 p.m. (Poster)
Abstract: #3236
Location: Hall F, Poster Section 9

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIADas approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit [ http://www.ariad.com ] or follow us on [ Twitter ].


Publication Contributing Sources